CETP Inhibition in CVD Prevention: an Actual Appraisal

Belinda Di Bartolo, Kohei Takata, My Ngan Duong, Stephen J. Nicholls

Research output: Contribution to journalReview ArticleOtherpeer-review

13 Citations (Scopus)


By virtue of their effects on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and cellular cholesterol efflux, there is considerable interest in the potential use of pharmacological inhibitors of cholesteryl ester transfer protein (CETP) as a novel approach for cardiovascular disease prevention. This is supported by observations from genetic and animal studies suggesting that less CETP activity has favorable cardiovascular effects. Despite the adverse effects of the first CETP inhibitor to move forward in clinical development, torcetrapib, there remains considerable interest in developing alternative CETP inhibitors without the off-target effects of torcetrapib. The clinical development programs leading to a number of promising CETP inhibitors will be reviewed.

Original languageEnglish
Article number43
Number of pages6
JournalCurrent Cardiology Reports
Issue number5
Publication statusPublished - 1 May 2016
Externally publishedYes


  • Atherosclerosis
  • Cardiovascular disease
  • CETP inhibitors
  • Clinical trials
  • Lipids
  • Prevention

Cite this